Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

Hamburg, Germany; Paris, France, 08 March 2018

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH